Life sciences investments in Europe: room for optimism!

Our Managing Director Philipp Steinbach (middle) at the Plattform LifeSciences event.

Gloomy headlines dominate the news: the life sciences sector is said to be deep in a “funding winter.” Biotech IPOs are facing a tough year, venture capital is tightening, and market volatility isn't helping. But is the outlook really that grim - especially in Europe?

At last week’s network meeting of the Plattform Life Sciences at the IZB - Innovation and Start-up Center Biotechnology, our Managing Director, Selina Greuel, delivered a keynote that offered a more hopeful perspective. While the number of deals in European life sciences may have declined, Selina highlighted that total deal volume has been steadily increasing since 2022—suggesting a more nuanced and even optimistic picture.

Selina Greuel, Managing Director, presenting our keynotes.

Johannes Link from FCF Fox Corporate Finance GmbH echoed this sentiment, presenting data that underscored positive financing trends across the European market.

We also had the pleasure of hearing thought-provoking insights from keynote speakers including Dr. Stefanie Greifeneder (Taylor Wessing), Pascal Schweizer (Thermosome), Ralf Huss (BioM Biotech Cluster Development GmbH), Benedikt Mahr (WIPIT), Holger Bengs (BCNP Consultants GmbH), Andreas Huber (Bayern Kapital), and Florian Eckstein (Risk Partners GmbH).

Huge thanks to Markus Rieger, Nina Rieger, Urs Moesenfechtel, and Janina Schaipp for organizing such a fantastic event. Looking forward to the next one!